Psychiatric Disorders
International Partner
An Introduction to Psychiatric Disorders
Neuropsychiatric conditions (e.g. autism, ADHD, bipolar disorder, depression, schizophrenia), are leading causes of disability worldwide and constitute a substantial health burden. Advances in diagnosis, treatment and prevention of mental health conditions have included enhanced understanding of their genetic basis and the identification of modifiable risk factors. Emerging novel pharmacological strategies include ketamine, medical cannabis and guanfacine. Technologies such as deep-brain stimulation and transcranial magnetic stimulation are proving beneficial in a number of disorders. However, further understanding of the molecular processes involved in the pathogenesis of psychiatric disorders is needed.
Browse our gallery of video highlights and short articles from the conference hub, providing latest expert insights from major conferences and peer-reviewed articles from the journal portfolio.
Our supporting partners do not constitute an endorsement of the content on this page.
What if your medical degree could launch more than a clinical career? In this candid and compelling read, Dr Jon Edelson shares his lessons for early-career clinicians ready to think beyond the bedside and explore the business of medicine.
"I have learned to value meeting patients where they are, listening with empathy, and offering structure, which can build trust, strengthen compliance, and improve outcomes." Dr Anna Maria Laure, postgraduate trainee in psychiatry and psychotherapy at the Medical University ...
"it is great to find out that some reasoning and a prescription has helped someone turn their life around" Dr Alexander Lisinski, resident psychiatrist at Sahlgrenska University Hospital and researcher at the Department of Pharmacology, Sahlgrenska Academy, Gothenburg, Sweden, ...
In this episode, we explore the future of continuing medical education (CME) with the team behind touchIME. Hannah Fisher and Matthew Goodwin share insights into global and US trends, the importance of patient inclusivity and how educational outcomes are evolving to better measure the direct impact of learning on clinical practice and patient care.
From 4–6 June 2025, the 20th International Forum on Mood and Anxiety Disorders (IFMAD) will take place in Budapest, Hungary, marking a significant milestone for this long-standing event in psychiatric research and practice. Since its inception in 1999, IFMAD has brought together global experts to explore the latest advances in the understanding and treatment of mood and anxiety disorders.
In this episode, we’re joined by Bradley Love, Professor of Cognitive and Decision Sciences at UCL, ELLIS fellow, and creator of BrainGPT. We discuss how this large language model is poised to assist researchers in advancing their work.
Article highlights Multiple screening tests are available to screen patients for cognitive impairment, and the Confusion Assessment Method is a helpful test to screen for delirium in the immediate postoperative period. Medicine reconciliation and identification and removal of potentially inappropriate ...
While Alzheimer’s disease (AD), the most common cause of dementia, is perhaps best characterized by cognitive decline, more than 90% of patients with dementia exhibit behavioural and psychological symptoms of dementia.1 The Cache County Study on Memory in Aging describes ...
Log into your Touch Account
Earn and track your CME credits on the go, save articles for later, and follow the latest congress coverage.
Sign up with an Email
Or use a .
This Functionality is for
Members Only
Explore the latest in medical education and stay current in your field. Create a free account to track your learning.
